VOXZOGO vosoritide 1.2 mg powder for injection vial and diluent pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

voxzogo vosoritide 1.2 mg powder for injection vial and diluent pre-filled syringe

biomarin pharmaceutical australia pty ltd - vosoritide, quantity: 1.2 mg - injection, powder for - excipient ingredients: citric acid monohydrate; mannitol; methionine; polysorbate 80; sodium citrate dihydrate; trehalose dihydrate - voxzogo is indicated for the treatment of achondroplasia in paediatric patients whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

VOXZOGO vosoritide 0.56 mg powder for injection vial and diluent pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

voxzogo vosoritide 0.56 mg powder for injection vial and diluent pre-filled syringe

biomarin pharmaceutical australia pty ltd - vosoritide, quantity: 0.56 mg - injection, powder for - excipient ingredients: mannitol; sodium citrate dihydrate; citric acid monohydrate; polysorbate 80; trehalose dihydrate; methionine - voxzogo is indicated for the treatment of achondroplasia in paediatric patients whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

VOXZOGO vosoritide 0.4 mg powder for injection vial and diluent pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

voxzogo vosoritide 0.4 mg powder for injection vial and diluent pre-filled syringe

biomarin pharmaceutical australia pty ltd - vosoritide, quantity: 0.4 mg - injection, powder for - excipient ingredients: citric acid monohydrate; mannitol; polysorbate 80; methionine; trehalose dihydrate; sodium citrate dihydrate - voxzogo is indicated for the treatment of achondroplasia in paediatric patients whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

PALYNZIQ pegvaliase 20 mg/mL solution for injection pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

palynziq pegvaliase 20 mg/ml solution for injection pre-filled syringe

biomarin pharmaceutical australia pty ltd - pegvaliase, quantity: 20 mg - injection, solution - excipient ingredients: sodium chloride; trometamol; water for injections; trometamol hydrochloride; cinnamic acid - palynziq is indicated for the treatment of patients with phenylketonuria (pku) aged 16 years and older who have inadequate blood phenylalanine control despite prior management with available treatment options.

PALYNZIQ pegvaliase 2.5 mg/0.5 mL solution for injection pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

palynziq pegvaliase 2.5 mg/0.5 ml solution for injection pre-filled syringe

biomarin pharmaceutical australia pty ltd - pegvaliase, quantity: 2.5 mg - injection, solution - excipient ingredients: trometamol hydrochloride; trometamol; cinnamic acid; sodium chloride; water for injections - palynziq is indicated for the treatment of patients with phenylketonuria (pku) aged 16 years and older who have inadequate blood phenylalanine control despite prior management with available treatment options.

PALYNZIQ pegvaliase 10 mg/0.5 mL solution for injection pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

palynziq pegvaliase 10 mg/0.5 ml solution for injection pre-filled syringe

biomarin pharmaceutical australia pty ltd - pegvaliase, quantity: 10 mg - injection, solution - excipient ingredients: cinnamic acid; trometamol; sodium chloride; water for injections; trometamol hydrochloride - palynziq is indicated for the treatment of patients with phenylketonuria (pku) aged 16 years and older who have inadequate blood phenylalanine control despite prior management with available treatment options.

Vimizim 1mgml Concentrate for Solution for Infusion Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

vimizim 1mgml concentrate for solution for infusion

pharm-d sdn. bhd. - elosulfase alfa -

Naglazyme New Zealand - English - Medsafe (Medicines Safety Authority)

naglazyme

pharmacy retailing (nz) ltd t/a healthcare logistics - galsulfase 1 mg/ml - concentrate for infusion - 1 mg/ml - active: galsulfase 1 mg/ml excipient: polysorbate 80 sodium chloride sodium phosphate water for injection - naglazyme is indicated as long term enzyme replacement therapy in patients with mucopolysaccharidosis vi (mps vi, n-acetylgalactosamine 4-sulfatase deficiency, maroteaux-lamy syndrome).

Aldurazyme New Zealand - English - Medsafe (Medicines Safety Authority)

aldurazyme

pharmacy retailing (nz) ltd t/a healthcare logistics - laronidase 0.58 mg/ml (rch) - concentrate for infusion - 500 u/5ml - active: laronidase 0.58 mg/ml (rch) excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - aldurazyme is indicated as long-term enzyme replacement therapy in patients with mucopolysaccharidosis i (mps i; alpha-l-iduronidase deficiency) to treat the non-neurological manifestations of the disease.

PureMed Biomarine Fish Oil Plus Softgel Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

puremed biomarine fish oil plus softgel

bio-science marketing sdn. bhd. - omega-3 fish oil; squalene; vitamin e (d-alpha tocopherol) -